Trial: 202006183

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab with ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)

Phase

II

Principal Investigator

Adkins, Douglas

Disease Site

Ill-Defined Sites; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov